- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Galveston Today
By the People, for the People
ProImmune Partners with UTMB to Advance Infectious Disease Research
Collaboration leverages Ankyron technology to study viral proteins under high-containment conditions.
Apr. 15, 2026 at 5:06am
Got story updates? Submit your updates here. ›
Cutting-edge Ankyron technology and high-containment research facilities combine to accelerate the study of emerging viral threats.Galveston TodayProImmune, Ltd. has announced a new collaboration with the University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL) to accelerate research into high-consequence infectious diseases. The partnership will utilize ProImmune's innovative Ankyron technology to study viral proteins under maximum-containment conditions, potentially leading to breakthroughs in vaccine and therapeutic development.
Why it matters
This collaboration highlights a growing trend towards proactive pandemic preparedness. The ability to rapidly identify and study viral proteins is essential for developing effective countermeasures against emerging infectious diseases. Ankyron technology, combined with the expertise of institutions like UTMB GNL, represents a significant step forward in this effort.
The details
The initial focus of the collaboration will be on validating Ankyrons for several pathogens of major global health concern, including Bundibugyo virus, Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus, Human Enterovirus 71, and Mpox virus. These studies will be conducted in the BSL-4 laboratory of Dr. Courtney Woolsey at GNL. Ankyrons are engineered for high affinity and specificity to diverse protein targets, and can be rapidly developed for new and emerging disease targets, unlike traditional antibody-based methods.
- The collaboration was announced on April 15, 2026.
The players
ProImmune, Ltd.
A company that develops innovative Ankyron technology for studying infectious disease proteins.
University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL)
A research facility equipped to handle pathogens under maximum-containment conditions (BSL-4).
Dr. Courtney Woolsey
A researcher at the UTMB GNL who will oversee the studies using Ankyron technology.
Nikolai Schwabe
The Chief Executive Officer of ProImmune, Ltd.
What they’re saying
“Ankyrons and our powerful automated high throughput parallel discovery platform are particularly well suited for demanding research environments such as emerging infectious diseases, enabling detection and interrogation of viral proteins and study of multiple rapidly emerging infectious diseases simultaneously.”
— Nikolai Schwabe, Chief Executive Officer, ProImmune, Ltd.
What’s next
The collaboration will initially focus on validating Ankyrons for several high-consequence pathogens, with the goal of informing the development of next-generation vaccines and therapeutics.
The takeaway
This partnership leverages cutting-edge technology and world-class expertise to accelerate research into emerging infectious diseases, representing a significant step forward in strengthening global pandemic preparedness.
